TABLE 1.

Support for perniosis during the COVID‐19 pandemic being related to SARS‐CoV2

Clustering of perniosis‐like cases in cities with a high incidence of COVID‐19

Some affected individuals with associated mild symptoms that could be attributed to COVID‐19

Many affected individuals with documented prior exposure to an individual with COVID‐19

Prevalence in children > adults (unlike perniosis prior to the emergence of COVID‐19)

Absence of prior history of chilblains or associated disease (eg, lupus erythematosus)

Absence of a consistent laboratory abnormality (eg, antiphospholipid antibodies or cryoproteins)

Positive COVID‐19 testing in a small subset (either by RT‐PCR from nasopharyngeal swabs or positive serology for anti‐IgG, anti‐IgM, or anti‐IgA against SARS‐CoV2 proteins)